Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
10.1111/adb.12583 27 HernandezN
Recent trials have shown: Up to 20% body weight reduction with weekly GLP-1 agonists (Wilding et al., NEJM) Improvements in HbA1c, fasting glucose, and cardiovascular outcomes (Marso et al., NEJM) This drug class is now widely used for: Obesity (with or without diabetes) Type 2 diabetes PCOS-related insulin resistance Metabolic syndrome Common Side Effects and Patient Concerns Despite their benefits, GLP-1 agonists are not without risks or drawbacks
Wu et al., 2020)
This review provides a meticulous exploration of GLP-1, elucidating its origin, secretion, and the challenges associated with its clinical application due to its fragility in the presence of DPP-IV, resulting in a short half-life
US$ 22.76
US$ 26.62
US$ 25.98
